Two Breast Cancer Drugs Linked to Better Kidney Outcomes

In women with advanced breast cancer and kidney disease, abemaciclib and ribociclib were tied to better results than palbociclib.

Updated on Nov. 7, 2026 in Cancer

Isometric editorial illustration of two smooth capsules in a shallow dish beside a kidney-shaped solid on a plain clinical-white surface, evoking drug choices in kidney disease.
Two breast cancer drugs, abemaciclib and ribociclib, were linked to better kidney outcomes than palbociclib in women with advanced disease and kidney impairment, a large U.S. health records study found. AI Illustration. Upload story photo >

Researchers using a large U.S. electronic health records network compared three CDK4/6 inhibitor drugs in women with advanced kidney disease and hormone-receptor-positive, HER2-negative metastatic breast cancer. Two alternatives, abemaciclib and ribociclib, were associated with lower rates of treatment failure and death than palbociclib.

Why it matters

Pivotal trials of these drugs excluded patients with severe kidney disease, leaving clinicians with limited data on how the drugs perform in this group. The findings offer observational evidence that could help inform treatment choices for women whose kidney function limits their options.

This observational target-trial emulation used electronic health record data from the TriNetX network to compare three pairwise treatment groups, with 2-year treatment failure and all-cause mortality as co-primary outcomes. Ribociclib and abemaciclib were each associated with lower treatment-failure and mortality hazards than palbociclib, though mortality associations did not hold across all sensitivity analyses.

The players

TriNetX Global Collaborative Network

A global health research network that aggregates de-identified electronic health record data from healthcare organizations to support clinical studies.

The details

Because the pivotal trials defined kidney eligibility by serum creatinine, patients with CKD stage 4 or 5 were largely absent from the evidence base. The researchers built matched comparison groups from routine records to approximate what randomized trials would have tested. Ribociclib was also associated with a fall in acute kidney injury risk versus palbociclib, while abemaciclib's kidney injury risk was stable.

Timeline

  1. Outcomes were tracked over a 2-year follow-up period.

  2. The study was published on November 7, 2026.

Health Landscape

Pivotal CDK4/6 inhibitor trials excluded patients with CKD stage 4 to 5 by defining renal eligibility through serum creatinine, leaving that group underrepresented in the evidence base. This observational analysis offers an early look at outcomes in those excluded patients, though it does not replace randomized evidence.

Women with metastatic breast cancer and reduced kidney function may wish to ask their oncology team how kidney health factors into drug selection. Anyone with kidney disease alongside cancer should discuss treatment options with their physician, as these findings are observational and not a substitute for individualized care.

The takeaway

Observational data suggest that abemaciclib and ribociclib may be associated with better outcomes than palbociclib in women with advanced kidney disease, a group pivotal trials largely excluded. Clinicians and patients should review these preliminary findings together and weigh them against randomized evidence when planning care.

Further reading

For broader context on treatment approaches, explore our Cancer coverage.

Source note: This article includes information reported by Nature.